Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

Also called NCT07541456

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
Dr. Zarmina Younes (from the registry)
Registry
  • NCT NCT07541456
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07541456. Randomized; single masking; primary purpose treatment. Start 2025-06-09 (actual); primary completion 2025-11-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes
Acronym
EMPA-BP
Condition
Type 2 Diabetes Mellitus
Condition
Hypertension
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Metformin
Lead sponsor
Dr. Zarmina Younes (class: other)

Record details

Record id
cardio:ct-nct07541456
Content hash
f28e3f7aafb7f188936f745e051037b3c158ce75e553ea01f42b52e4b191361b